Stock SONN SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sonnet BioTherapeutics Holdings, Inc.

Equities

SONN

US83548R3030

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/05/2024 BST 		5-day change 1st Jan Change
1.65 USD -5.17% Intraday chart for Sonnet BioTherapeutics Holdings, Inc. -8.84% -5.17%
03-11 Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street MT
03-11 Top Premarket Gainers MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street
Top Premarket Gainers
Sonnet BioTherapeutics Holdings, Inc. Announces First Phase 1b/2a Clinical Trial of SON-080
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
Sector Update: Health Care Stocks Retreating Late Afternoon
Top Midday Decliners
Top Premarket Decliners
Sector Update: Health Care Stocks Lower in Late Afternoon Trading
Sector Update: Health Care Stocks Lower Thursday Afternoon
Sonnet BioTherapeutics to Implement 1-for-22 Reverse Stock Split; Shares Fall
Sector Update: Health Care Stocks Decreasing Late Afternoon
Sector Update: Health Care Stocks Lower Wednesday Afternoon
Sector Update: Health Care
Top Midday Gainers
Sonnet BioTherapeutics Says FDA Accepts IND for Trial of Ovarian Cancer Treatment; Shares Jump
Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US
Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
Sonnet BioTherapeutics to Raise $2.3 Million in Registered Direct Offering, Private Placement; Shares Fall
Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SONN Stock
  4. News Sonnet BioTherapeutics Holdings, Inc.
  5. Other languages